Five patients in Part 2 achieved a PR while receiving pemigatinib 13.5 mg treatment (ID, n = 1; CD, n = 4) for the following tumors: cholangiocarcinoma with a locally identified FGFR2 translocation; gall bladder cancer with FGF3/4/19 amplification; breast cancer with FGFR2 amplification; urothelial tract/bladder cancer with FGF3/4/19 amplification and FGFR3 alteration; and “other” (apocrine sweat gland carcinoma) with FGFR2 amplification. Here, FGF3 is linked to cholangiocarcinoma.